Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients

被引：24

作者：

Nakamura, Yasuhiro ^{[1
,27
]}

Namikawa, Kenjiro ^{[2
]}

Kiniwa, Yukiko ^{[3
]}

Kato, Hiroshi ^{[4
]}

Yamasaki, Osamu ^{[5
]}

Yoshikawa, Shusuke ^{[6
]}

Maekawa, Takeo ^{[7
]}

Matsushita, Shigeto ^{[8
]}

Takenouchi, Tatsuya ^{[9
]}

Inozume, Takashi ^{[10
]}

Nakai, Yasuo ^{[11
]}

Fukushima, Satoshi ^{[12
]}

Saito, Shintaro ^{[13
]}

Otsuka, Atsushi ^{[14
,15
]}

Fujimoto, Noriki ^{[16
]}

Isei, Taiki ^{[17
]}

Baba, Natsuki ^{[18
]}

Matsuya, Taisuke ^{[19
]}

Tanaka, Ryo ^{[20
]}

Kaneko, Takahide ^{[21
]}

Onishi, Masazumi ^{[22
]}

Kuwatsuka, Yutaka ^{[23
]}

Nagase, Kotaro ^{[24
]}

Onuma, Takehiro ^{[25
]}

Nomura, Motoo ^{[26
]}

Umeda, Yoshiyasu ^{[1
,20
]}

Yamazaki, Naoya ^{[2
]}

机构：

[1] Saitama Med Univ, Dept Skin Oncol Dermatol, Int Med Ctr, Saitama, Japan

[2] Natl Canc Ctr, Dept Dermatol Oncol, Tokyo, Japan

[3] Shinshu Univ, Dept Dermatol, Matsumoto, Japan

[4] Nagoya City Univ, Dept Geriatr & Environm Dermatol, Grad Sch Med Sci, Nagoya, Japan

[5] Okayama Univ, Dept Dermatol, Dent & Pharmaceut Sci, Grad Sch Med, Okayama, Japan

[6] Shizuoka Canc Ctr, Dermatol Div, Shizuoka, Japan

[7] Jichi Med Univ, Dept Dermatol, Tochigi, Japan

[8] Natl Hosp Org, Dept Dermato Oncol Dermatol, Kagoshima Med Ctr, Kagoshima, Japan

[9] Niigata Canc Ctr Hosp, Dept Dermatol, Niigata, Japan

[10] Chiba Univ, Dept Dermatol, Chiba, Japan

[11] Mie Univ, Dept Dermatol, Mie, Japan

[12] Kumamoto Univ, Fac Life Sci, Dept Dermatol & Plast Surg, Kumamoto, Japan

[13] Gunma Univ, Dept Dermatol, Grad Sch Med, Maebashi, Japan

[14] Kyoto Univ, Dept Dermatol, Kyoto, Japan

[15] Kindai Univ Hosp, Dept Dermatol, Osaka, Japan

[16] Shiga Univ Med Sci, Dept Dermatol, Otsu, Japan

[17] Osaka Int Canc Inst, Dept Dermatol Oncol, Osaka, Japan

[18] Univ Fukui, Dept Dermatol, Fukui, Japan

[19] Asahikawa Med Univ, Dept Dermatol, Asahikawa, Japan

[20] Kawasaki Med Sch, Dept Dermatol, Kurashiki, Japan

[21] Juntendo Univ, Dept Dermatol, Urayasu Hosp, Chiba, Japan

[22] Iwate Med Univ, Dept Dermatol, Iwate, Japan

[23] Nagasaki Univ, Dept Dermatol, Nagasaki, Japan

[24] Saga Univ, Fac Med, Dept Internal Med, Div Dermatol, Saga, Japan

[25] Univ Yamanashi, Dept Dermatol, Yamanashi, Japan

[26] Kyoto Univ, Dept Clin Oncol, Kyoto, Japan

[27] Saitama Med Univ, Dept Skin Oncol Dermatol, Int Med Ctr, 1397-1 Yamane, Saitama 3501298, Japan

来源：

EUROPEAN JOURNAL OF CANCER | 2022年 / 176卷

关键词：

CTLA-4; antigen; Immunotherapy; Ipilimumab; Melanoma; Nivolumab; Pembrolizumab; Programmed cell death 1 receptor; Retrospective studies; Japan; SINGLE-ARM; OPEN-LABEL; PD-1; BLOCKADE; PHASE-II; MUCOSAL; IPILIMUMAB; INHIBITORS; NIVOLUMAB; MUTATION; SAFETY;

D O I：

10.1016/j.ejca.2022.08.030

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Although anti-PD-1 antibody monotherapy (PD-1) is commonly used to treat advanced acral melanoma (AM), its efficacy is limited. Further, data on the efficacy of PD-1 plus anti-CTLA-4 antibody (PD-1+CTLA-4) for the treatment of AM are limited. Therefore, we compared the efficacy of PD-1+CTLA-4 and PD-1 in the treatment of Japanese patients with advanced AM. Methods: This retrospective study evaluated patients with advanced AM who were treated with PD-1 or PD-1+CTLA-4 as first-line immunotherapy in 24 Japanese institutions between 2014 and 2020. Treatment efficacy focussing on the objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) was compared between the two groups. Results: In total, 254 patients (palm and sole melanoma [PSM], n = 180; nail apparatus melanoma [NAM], n = 74) were included. Among the patients with PSM, the ORR (19% vs. 31%; P = 0.44), PFS (5.9 vs. 3.2 months; P = 0.74), and OS (23.1 vs. not reached; P = 0.55) did not differ significantly between the PD-1 and PD-1+CTLA-4 groups. Among the patients with NAM, the ORR (61% vs. 10%; P < 0.001) was significantly higher and PFS was longer (6.4 vs. 3.8 months; P = 0.10) in the PD-1+CTLA-4 group than in the PD-1 group. Cox multivariate analysis demonstrated that PD-1+CTLA-4 is an independent predictor of a favourable PFS in patients with NAM (P = 0.002). Conclusions: The efficacy of PD-1+CTLA-4 is not superior to that of PD-1 for the treatment of advanced PSM. However, PD-1+CTLA-4 may be more efficacious than PD-1 for the treatment of advanced NAM. (C) 2022 Elsevier Ltd. All rights reserved.

引用

页码：78 / 87

页数：10

共 50 条

[31] Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, efficacy, and Limitations
Seidel, Judith A.
Otsuka, Atsushi
Kabashima, Kenji
FRONTIERS IN ONCOLOGY, 2018, 8
[32] Combination Therapy with Anti-CTLA-4 and Anti-PD-1 Leads to Distinct Immunologic Changes In Vivo
Das, Rituparna
Verma, Rakesh
Sznol, Mario
Boddupalli, Chandra Sekhar
Gettinger, Scott N.
Kluger, Harriet
Callahan, Margaret
Wolchok, Jedd D.
Halaban, Ruth
Dhodapkar, Madhav V.
Dhodapkar, Kavita M.
JOURNAL OF IMMUNOLOGY, 2015, 194 (03) : 950 - 959
[33] Haemophagocytic lymphohistiocytosis as a complication of combination anti-PD-1 and anti-CTLA-4 checkpoint inhibitor immunotherapy for metastatic melanoma, and the outcome of rechallenge with single-agent anti-PD-1 immunotherapy
Holmes, Zachary
Courtney, Ashling
Hiong, Alison
BMJ CASE REPORTS, 2022, 15 (08)
[34] Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma
Pollack, M. H.
Betof, A.
Dearden, H.
Rapazzo, K.
Valentine, I.
Brohl, A. S.
Ancell, K. K.
Long, G. V.
Menzies, A. M.
Eroglu, Z.
Johnson, D. B.
Shoushtari, A. N.
ANNALS OF ONCOLOGY, 2018, 29 (01) : 250 - 255
[35] Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study
Shui, Irene M.
Liu, Xiao Qiao
Zhao, Qing
Kim, Seung Tae
Sun, Yuan
Yearley, Jennifer H.
Choudhury, Tasmiah
Webber, Andrea L.
Krepler, Clemens
Cristescu, Razvan
Lee, Jeeyun
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (07)
[36] Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma
Zimmer, Lisa
Apuri, Susmitha
Eroglu, Zeynep
Kottschade, Lisa A.
Forschner, Andrea
Gutzmer, Ralf
Schlaak, Max
Heinzerling, Lucie
Krackhardt, Angela M.
Loquai, Carmen
Markovic, Svetomir N.
Joseph, Richard W.
Markey, Kelly
Utikal, Jochen S.
Weishaupt, Carsten
Goldinger, Simone M.
Sondak, Vernon K.
Zager, Jonathan S.
Schadendorf, Dirk
Khushalani, Nikhil I.
EUROPEAN JOURNAL OF CANCER, 2017, 75 : 47 - 55
[37] Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials
Yun, Seongseok
Vincelette, Nicole D.
Green, Myke R.
Hendrickson, Andrea E. Wahner
Abraham, Ivo
CANCER MEDICINE, 2016, 5 (07): : 1481 - 1491
[38] Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study
van Zeijl, Michiel C. T.
Haanen, John B. A. G.
Wouters, Michel W. J. M.
de Wreede, Liesbeth C.
Jochems, Anouk
Aarts, Maureen J. B.
van den Berkmortel, Franchette W. P. J.
de Groot, Jan Willem B.
Hospers, Geke A. P.
Kapiteijn, Ellen W.
Piersma, Djura
van Rijn, Rozemarijn S.
Suijkerbuijk, Karijn P. M.
ten Tije, Albert J.
van der Veldt, Astrid A. M.
Vreugdenhil, Gerard
van der Hoeven, Koos J. M.
van den Eertwegh, Alfons J. M.
JOURNAL OF IMMUNOTHERAPY, 2020, 43 (08) : 256 - 264
[39] Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Boutros, Celine
Tarhini, Ahmad
Routier, Emilie
Lambotte, Olivier
Ladurie, Francois Leroy
Carbonnel, Franck
Izzeddine, Hassane
Marabelle, Aurelien
Champiat, Stephane
Berdelou, Armandine
Lanoy, Emilie
Texier, Matthieu
Libenciuc, Cristina
Eggermont, Alexander M. M.
Soria, Jean-Charles
Mateus, Christine
Robert, Caroline
NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (08) : 473 - 486
[40] Bispecific anti-PD-1/CTLA-4 antibody for advanced solid tumors
Perez-Santos, Martin
PHARMACEUTICAL PATENT ANALYST, 2020, 9 (05) : 149 - 154

← 1 2 3 4 5 →